Red light emission of Mn doped beta-tricalcium phosphate -Ca3(PO4)2

This paper is the first report on the red light emission of manganese (Mn) doped beta-tricalcium phosphate (b-Ca3(PO4)2, TCP) synthesis by co-precipitation method followed by thermal annealing. The annealed Mn doped TCP phosphor showed dominant spheres with a diameter of about 500 nm. The influences of the Mn concentration, annealing temperature, and atmospheres on the photoluminescence intensities of the phosphors were investigated and the results indicate that the annealing temperatures and Mn concentrations are the main factors. The phosphor showed visible emission peaks appeared at about 660 nm and 580 nm results in from the 4T1-6A1 transitions within Mn2+ ion. The Mn-TCP phosphor may serve as a candidate for light-emitting diode application in agriculture lighting. Keywords. Hydroxyapatite; manganese; luminescence; tricalcium phosphate

No increase of drug-resistant HIV type 1 prevalence among drug-naive individuals in northern vietnam

We reported previously that the prevalence of drug-resistant HIV-1 among antiretroviral therapy (ART)-naive individuals in Northern Vietnam was 2.9% in 2007 and 6.2% in 2008. To investigate the continuing trend of prevalence, we collected plasma samples from 958 individuals in Hai Phong and Hanoi in 2009, extracted viral RNA from HIV-1 antibody-positive samples, and analyzed them genetically. HIV-1 antibody prevalence was 26.8% in injecting drug users (n=302), 13.4% in female sex workers (n=284), 0.5% in blood donors (n=206), and 0.6% in pregnant women (n=166). All HIV-1 strains were CRF01-AE. Nonnucleoside reverse-transcriptase inhibitor resistance mutations were found in two (2.0%) of the 102 successfully analyzed cases (one case with the Y181C and one with the K101E). No nucleoside reverse-transcriptase inhibitor resistance or protease inhibitor resistance mutations were detected. The prevalence of circulating ART-resistant HIV-1 in Northern Vietnam did not increase from 2007 to 2009, although the rate of ART coverage did increase. © 2012, Mary Ann Liebert, Inc

Electrochemical Determination of Paracetamol Using Fe 3

The synthesis of magnetic iron oxide/reduced graphene oxide (Fe3O4/rGO) and its application to the electrochemical determination of paracetamol using Fe3O4/rGO modified electrode were demonstrated. The obtained materials were characterized by means of X-ray diffraction (XRD), nitrogen adsorption/desorption isotherms, X-ray photoelectron spectroscopy (XPS), transmission electron microscope (TEM), Fourier transform infrared spectroscopy (FTIR), and magnetic measurement. The results showed that Fe3O4/rGO composite exhibited high specific surface area, and its morphology consists of very fine spherical particles of Fe3O4 in nanoscales. Fe3O4/rGO was used as an electrode modifier for the determination of paracetamol by differential pulse-anodic stripping voltammetry (DP-ASV). The preparation of Fe3O4/rGO-based electrode and some factors affecting voltammetric responses were investigated. The results showed that Fe3O4/rGO is a potential electrode modifier for paracetamol detection by DP-ASV with a low limit of detection. The interfering effect of uric acid, ascorbic acid, and dopamine on the current response of paracetamol has been reported. The repeatability, reproducibility, linear range, and limit of detection were also addressed. The proposed method could be applied to the real samples with satisfactory results

Fe3O4/Reduced Graphene Oxide Nanocomposite: Synthesis and Its Application for Toxic Metal Ion Removal

The synthesis of reduced graphene oxide modified by magnetic iron oxide (Fe3O4/rGO) and its application for heavy metals removal were demonstrated. The obtained samples were characterized by X-ray diffraction (XRD), nitrogen adsorption/desorption isotherms, X-ray photoelectron spectroscopy (XPS), Fourier transform infrared spectroscopy (FT-IR), and magnetic measurement. The results showed that the obtained graphene oxide (GO) contains a small part of initial graphite as well as reduced oxide graphene. GO exhibits very high surface area in comparison with initial graphite. The morphology of Fe3O4/rGO consists of very fine spherical iron nanooxide particles in nanoscale. The formal kinetics and adsorption isotherms of As(V), Ni(II), and Pb(II) over obtained Fe3O4/rGO have been investigated. Fe3O4/rGO exhibits excellent heavy metal ions adsorption indicating that it is a potential adsorbent for water sources contaminated by heavy metals

Improvement of Hydrophilicity for Polyamide Composite Membrane by Incorporation of Graphene Oxide-Titanium Dioxide Nanoparticles

In this work, the polyamide (PA) membrane surface has been modified by coating of nanomaterials including graphene oxide (GO) and titanium dioxide (TiO2) to enhance membrane separation and antifouling properties. The influence of surface modification conditions on membrane characteristics has been investigated and compared with a base membrane. Membrane surface properties were determined through scanning electron microscope (SEM) images and Fourier transform infrared-attenuated total reflectance (FTIR-ATR) spectroscopy. Membrane separation performance was determined through the possibility for the removal of methylene blue (MB) in water. Membrane antifouling property was evaluated by the maintained flux ratios (%) after 120 minutes of filtration. The experimental results showed that the appearance of hydrophilic groups after coating of GO and TiO2 nanocomposite materials with or without UV irradiation onto membrane surface made an improvement in the separation property of the coated membranes. The membrane flux increased from 28% to 61%; meanwhile, the antifouling property of the coated membranes was improved clearly, especially for UV-irradiated PA/GO-TiO2 membrane

TiO2/Diazonium/Graphene Oxide Composites: Synthesis and Visible-Light-Driven Photocatalytic Degradation of Methylene Blue

In the present article, the synthesis of TiO2/diazonium/graphene oxide and its photocatalytic activity for methylene blue (MB) degradation have been demonstrated. The functionalization of graphene oxide (GO) with diazonium salt (diazonium-GO) was conducted for enhancing the dispersibility of GO in distilled water. TiO2 was highly dispersed in diazonium-GO to form TiO2/diazonium/graphene. The obtained specimens were characterized by X-ray diffraction, FT-IR spectroscopy, Raman spectroscopy, UV-Vis spectroscopy, scanning electron microscope, transmission electron microscopy, and X-ray photoelectron spectroscopy. It was found that the TiO2 phase in TiO2/diazonium/GO composites can be controlled by adjusting the amount of ethanol or titanium oxide in the reactant mixture. The obtained composites exhibited photocatalytic activities for methylene blue degradation (MB). The composite with ac. 70% anatase can provide the highest MB degradation efficiency. The studying of some intermediates for MB photocatalytic degradation using LC-MS showed that structure of MB by the cleavage and oxidation of one or more of the methyl group substituent on the amine groups lead to form compounds with low molecular masses. Total organic carbon studies confirmed a complete mineralization of MB. The present catalyst was stable and recyclable after three times with a negligible loss of catalytic activity. In addition, the TiO2/diazonium/GO can also photocatalyze for the degradation of some other dyes (phenol, methyl red, and Congo red)

Simultaneous Voltammetric Determination of Uric Acid, Xanthine, and Hypoxanthine Using CoFe2O4/Reduced Graphene Oxide-Modified Electrode

In the present paper, the synthesis of cobalt ferrite/reduced graphene oxide (Co2Fe2O4/rGO) composite and its use for the simultaneous determination of uric acid (UA), xanthine (XA), and hypoxanthine (HX) is demonstrated. Cobalt ferrite hollow spheres were synthesized by using the carbonaceous polysaccharide microspheres prepared from a D-glucose solution as templates, followed by calcination. The CoFe2O4/rGO composite was prepared with the ultrasound-assisted method. The obtained material was characterized by using X-ray diffraction, scanning electron microscopy, X-ray photoelectron spectroscopy, EDX elemental mapping, and nitrogen adsorption/desorption isotherms. The electrochemical behavior of UA, XA, and HX on the CoFe2O4/rGO-modified electrode was studied with cyclic voltammetry and differential pulse voltammetry (DPV). The modified electrode exhibits excellent electrocatalytic activity towards the oxidation of the three compounds. The calibration curves for UA, XA, and HX were obtained over the range of 2.0–10.0 μM from DPV. The limits of detection for UA, XA, and HX are 0.767, 0.650, and 0.506 μM, respectively. The modified electrode was applied to the simultaneous detection of UA, XA, and HX in human urine, and the results are consistent with those obtained from the high-performance liquid chromatography technique

Voltammetric Determination of Rhodamine B Using a ZIF-67/Reduced Graphene Oxide Modified Electrode

In the present article, the synthesis of zeolite imidazolate framework-67/reduced graphene oxide (ZIF-67/rGO) and voltammetric determination of Rhodamine B (RhB) are demonstrated. The obtained materials were characterized by X-ray diffraction, scanning electron microscopy, transmission electron microscopy, X-ray photoelectron spectroscopy, and nitrogen adsorption/desorption isotherms. It was found that the ZIF-67/rGO composite consists of ZIF-67 nano-particles highly dispersed on the rGO matrix and possesses a high specific surface area. Because of the synergistic effect of good conductivity of rGO and high surface area of ZIF-67, the ZIF-67/rGO—modified glassy carbon electrode exhibits good electrochemical behavior toward Rhodamine B (RhB) oxidation. The use of this electrode to quantitate RhB with differential pulse voltammetric method was successful with a broad linear range, from 0.96 to 44.07 μg.L-1 of RhB and a low limit of detection of 1.79 μg.L-1. The procedure was able to be applied to quantitatively determine RhB content in several food samples with an exceptional recovery rate (98-103%). The quantitative results highly agreed with that provided by high-performance liquid chromatography, revealing that this material is promising in in situ monitoring of other illegal additives in food

Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis

The optimal time to initiate antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-associated tuberculous meningitis is unknown. We conducted a randomized, double-blind, placebo-controlled trial of immediate versus deferred ART in patients with HIV-associated tuberculous meningitis to determine whether immediate ART reduced the risk of death. Antiretroviral drugs (zidovudine, lamivudine, and efavirenz) were started either at study entry or 2 months after randomization. All patients were treated with standard antituberculosis treatment, adjunctive dexamethasone, and prophylactic co-trimoxazole and were followed up for 12 months. We conducted intention-to-treat, per-protocol, and prespecified subgroup analyses. A total of 253 patients were randomized, 127 in the immediate ART group and 126 in the deferred ART group; 76 and 70 patients died within 9 months in the immediate and deferred ART groups, respectively. Immediate ART was not significantly associated with 9-month mortality (hazard ratio [HR], 1.12; 95% confidence interval [CI], .81-1.55; P = .50) or the time to new AIDS events or death (HR, 1.16; 95% CI, .87-1.55; P = .31). The percentage of patients with severe (grade 3 or 4) adverse events was high in both arms (90% in the immediate ART group and 89% in the deferred ART group; P = .84), but there were significantly more grade 4 adverse events in the immediate ART arm (102 in the immediate ART group vs 87 in the deferred ART group; P = .04). Immediate ART initiation does not improve outcome in patients presenting with HIV-associated tuberculous meningitis. There were significantly more grade 4 adverse events in the immediate ART arm, supporting delayed initiation of ART in HIV-associated tuberculous meningitis. Clinical Trials Registration. ISRCTN6365909